Interview with Mike “Zappy” Zapolin

Can Psychedelics Treat Alcoholism? New Psilocybin & DMT Studies Say YES

Wakeful Travel Kickstarter: https://www.kickstarter.com/projects/920110985/wakeful-travel-journals-support-your-transformation?ref=f1y202

In today’s episode, we dive into two pre-clinical studies testing psychedelics’ effectiveness in treating alcohol-related illnesses.

In the first, researchers tested psilocybin (magic mushrooms) on mice who got addicted to alcohol. They found that the psilocybin helped repair a part of their brain that alcohol abuse damaged. This helped the mice make less neurotic decisions, and helped them abstain from alcohol.

This is promising, and if it can be repeated in humans, it would be a huge step forward in treating alcoholism.

The second study looked at the Ayahuasca brew, which has as its main psychoactive ingredient DMT. In this study, the researchers found that the mice who took the ayahuasca were less likely to seek out more alcohol.

Again, if this can be replicated in humans, it would show the powerful benefits of psychedelic medicines to treat alcoholism.

Psychedelics and mental health have long been a topic of research, and we are finally getting data that psychedelics like psilocybin and DMT may be effective in treating a variety of mental health conditions, such as alcoholism.

Links:
Psilocybin Study
https://www.science.org/doi/10.1126/sciadv.abh2399#F5

Psilocybin article
https://www.inverse.com/mind-body/psilocybin-repairs-alcohol-brain-damage

Ayahuasca study:
https://pubmed.ncbi.nlm.nih.gov/34822961/

Enjoy the episode!
Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com
Video editing: @themyaholy

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#Psilocybin #DMT #Psychedelics

Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd:
www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20

Join our Newsletter (scroll to the bottom of the page and sign up):
https://psychedelicspotlight.com/

Follow us on Twitter:
The Psychedelic Investor: @PSYCBiz
Psychedelic Spotlight: @PsycSpotlight

Follow us on Instagram:
@psycbiz
@psycspotlight

❗❗❗ The Psychedelic Investor will be changing its name to PSYC Business very soon.
Stay tuned for more updates!

In today’s episode, we discuss MindMed (Nasdaq: MNMD, NEO:MMED) and its Phase 2 LSD Trial Treating Anxiety Results.

MindMed (Nasdaq: MNMD, NEO:MMED) finally gave the world a glimpse into its LSD-as-medicine project today.

Speaking at the highly anticipated PSYCH Symposium in London, researchers Prof. Matthias Liechti and Dr. Friederike Holze presented topline data of a Phase 2, double-blind, placebo-controlled study, attempting to treat anxiety disorders with LSD in 46 patients. Patients received 200 µg (micrograms) of LSD, which is considered a large dose.

The results were very positive, though perhaps not paradigm shifting — yet.

The primary endpoint of the study was the reduction in anxiety levels 16 weeks after the administration of LSD. They measured this using a questionnaire called the State Trait Anxiety Inventory, better known by its acronym STAI. In short, a person can have a score between 0 and 63, with the higher the score, the worse the anxiety.

The study found that 65% of patients saw their anxiety levels drop by at least 30% from where they were before treatment, 16 weeks after dosing. This compared to only 9% of patients in the placebo arm reaching that 30% level. The average reduction in the STAI was 16.2 points.

Importantly, there was only one serious adverse event in the trial, which consisted of “acute transient anxiety and delusions” during the LSD experience. It does not appear that this patient had any troubles once the effects wore off. In sum, the administration of large doses of LSD appears to be very safe, even if one person did have a particularly bad experience during the dosing.

Furthermore, when looking at secondary variables that measure depression, anxiety and other major psychiatric symptoms (Hamilton Depression Scale, Beck Depression Index, Symptom-Check-List-90-R) the results “showed similarly rapid and sustained responses consistent with a lasting treatment effect.”

In sum, according to MindMed, the topline data demonstrates “the significant, rapid, durable, and beneficial effects of LSD and potential to safely mitigate symptoms of anxiety and depression.”

Interested in reading the article? Click here: 👇

MindMed’s Phase 2 LSD Trial Treating Anxiety Was a Success
https://psychedelicspotlight.com/mindmed-lsd-anxiety-phase-2-trial-psych-symposium/

#MindMed #Anxiety #MNMD

Hello Psychedelic Investors! The topic of today’s video is “Does microdosing mushrooms work?” We usually talk about investing in psychedelic stocks and companies inspired by microdosing psychedelics with the mission to cure depression, anxiety, adhd, etc. But we never really dove deep into the science of microdosing. Does Microdosing Magic Mushrooms really work? So before investing in companies like MindMed (MMED/MMEDF), Compass Pathways (CMPS), Numi, Field Trip Health (FTRP) or Atai Life Sciences, listening to someone who’s got a personal experience with psychedelics might not be such a bad idea.

One of the reasons behind the interview with pro in the Microdosing psilocybin realm is that recent studies have shown that the benefits of microdosing can be attributed completely to placebo effects. That’s why I decided to have a talk with Sena Maria. Sena is passionate about working with the fungi realm to support our collective evolution. Coming from Google in Silicon Valley she took a big life pivot and has spent the last 5 years learning from the plants. After supporting hundreds of people in getting started with microdosing, she now shares what she’s learned on her YouTube channel The Medicine of Being Human and her instagram @sena__maria.

So what do you guys think? Is Microdosing Psychedelics the Future of Medicine? Hopefully some of the new MMED or CMPS or any other psychedelic stocks investors got some value in this! What do you guys think?

You can learn more about microdosing in her popular webinar Microdosing For Resilience at www.medicineofbeinghuman.com

Timestamps:

0:00 – Intro
1:11 – What is Microdosing & How does it Work?
2:55 – Microdosing Benefits
7:28 – Why Microdosing? ( Regimen & Protocols)
14:12 – Discussing microdosing & placebo effects
19:21 – Personal Microdosing Experiences & Consistency
24:09 – Microdosing Advice for Beginners

#PsychedelicStocks #MindMed #MicrodosingPsilocybin

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.